Sotagliflozin is Used for reducing the risk of cardiovascular events in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. It was first introduced by Lexicon Pharmaceuticals Inc in its drug Inpefa on May 26, 2023.

Sotagliflozin Patents

Given below is the list of patents protecting Sotagliflozin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Inpefa	US7781577	Inhibitors of sodium glucose co-transporter 2 and methods of their use	May 04, 2028	Lexicon Pharms Inc
Inpefa	US8217156	Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use	Oct 07, 2030	Lexicon Pharms Inc
Inpefa	US8476413	Sulfanyl-tetrahydropyran-based compounds and methods of their use	May 29, 2028	Lexicon Pharms Inc

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳